an increased frequency of T cells expressing the co-inhibitory receptors KLRG1 and TIGIT was detected. Importantly, the latter signature resembles the CD8 + T-cell signature associated with a ...
Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint.
Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint.